MedPath

Nielsen BioSciences, Inc.

Nielsen BioSciences, Inc. logo
🇺🇸United States
Ownership
Private
Established
2013-01-01
Employees
1
Market Cap
-
Website
http://www.nielsenbio.com

Clinical Trials

6

Active:2
Completed:4

Trial Phases

2 Phases

Phase 2:3
Phase 3:2

Drug Approvals

1

FDA:1

Drug Approvals

Spherusol

Approval Date
Dec 1, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (60.0%)
Phase 3
2 (40.0%)

Candin for the Treatment of Common Warts

Phase 3
Active, not recruiting
Conditions
Common Warts (Verruca Vulgaris)
Interventions
Drug: Candin, Intradermal Solution
Drug: Placebo
First Posted Date
2023-06-05
Last Posted Date
2025-02-06
Lead Sponsor
Nielsen BioSciences, Inc.
Target Recruit Count
330
Registration Number
NCT05889845
Locations
🇺🇸

Cahaba Dermatology, Birmingham, Alabama, United States

🇺🇸

Arkansas Pediatric Clinic, Bryant, Arkansas, United States

🇺🇸

Johnson Dermatology, Ft. Smith, Arkansas, United States

and more 15 locations

Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

Phase 2
Completed
Conditions
Warts
First Posted Date
2015-03-19
Last Posted Date
2019-06-04
Lead Sponsor
Nielsen BioSciences, Inc.
Target Recruit Count
243
Registration Number
NCT02393417
Locations
🇺🇸

Johnson Dermatology, Fort Smith, Arkansas, United States

🇺🇸

Northwest Arkansas Clinical Trials Center PLLC, Rogers, Arkansas, United States

🇺🇸

California Dermatology and Clinical Research Institute, Encinitas, California, United States

and more 12 locations

Candin Safety & Efficacy Study for the Treatment of Warts

Phase 2
Completed
Conditions
Warts
Human Papilloma Virus
First Posted Date
2012-12-28
Last Posted Date
2021-02-04
Lead Sponsor
Nielsen BioSciences, Inc.
Target Recruit Count
39
Registration Number
NCT01757392
Locations
🇺🇸

Johnson Dermatology, Fort Smith, Arkansas, United States

A Multi-center Study of Spherule-Derived Coccidioidin

Phase 3
Completed
Conditions
Coccidioidomycosis
First Posted Date
2008-06-04
Last Posted Date
2013-10-29
Lead Sponsor
Nielsen BioSciences, Inc.
Target Recruit Count
113
Registration Number
NCT00690092
Locations
🇺🇸

Health Sciences Center AVAHCS, Univ. of Arizona, Tucson, Arizona, United States

🇺🇸

Kern Facility Medical Group, Bakersfield, California, United States

🇺🇸

Blair Clinic, Blair, Nebraska, United States

and more 1 locations

Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen

Phase 2
Completed
Conditions
Cutaneous Leishmaniasis
First Posted Date
2008-03-11
Last Posted Date
2013-11-20
Lead Sponsor
Nielsen BioSciences, Inc.
Target Recruit Count
50
Registration Number
NCT00633009
Locations
🇺🇸

California Research Foundation, San Diego, California, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.